FIG 4.

Susceptibility of HBV core variants to inhibition by NVR 3-778. HepG2 cells transiently transfected with wild-type HBV or the Y118F core variant (A), the I105L, I105T, or I105V core variant (B), or the T109S, T109M, or T109I core variant (C) were incubated with increasing concentrations of NVR 3-778 for 3 days. Intracellular encapsidated HBV DNA levels were monitored and compared with those for untreated cells. The dose-response curves for NVR 3-778 against HBV containing the wild-type genome are shown as dashed lines. Data points represent mean values from at least three independent antiviral studies, and standard deviations are shown as error bars.